|
|
|||||||
| Welcome to the Neuroscience Forum. | ||||
| Welcome to the Neuroscience Forum. If this is your first visit please register to be able to post and remove ads. To start viewing messages, select the forum that you want to visit from the selection below. |
 |
|
|
Thread Tools | Display Modes |
07-28-2010, 05:04 PM
|
#1 (permalink) |
|
Senior Member
Join Date: Feb 2009
Posts: 3,540
|
Seaside Therapeutics Reports Data From Randomized, Placebo-Controlled Phase 2 Study I
Seaside Therapeutics, Inc. announced data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population...
Read More from Medical News Today... |
|
|
|
| Thread Tools | |
| Display Modes | |
|
|
Linear Mode
